MedTrace Logo

Prospective Prolaris Value and Efficacy

NCT03152448 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1511

Last updated 2022-06-13

No results posted yet for this study

Summary

This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.

Conditions

Interventions

BEHAVIORAL

Prolaris

Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result

Sponsors & Collaborators

  • VA Salt Lake City Health Care System

    collaborator FED

  • Myriad Genetic Laboratories, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-01
Primary Completion
2022-03-21
Completion
2022-03-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03152448 on ClinicalTrials.gov